Zydus Gets USFDA Nod For Anaesthesia Drug

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Ephedrine Sulfate Injection USP, 50 mg/mL single-dose vials. The drug is generic equivalent of US Reference Listed Drug  Akovaz Injection. 

Ephedrine Sulfate Injection is indicated for the treatment of clinically important hypotension occurring in the setting of anaesthesia. The drug will be manufactured at the group’s injectable manufacturing facility at Jarod, near Vadodara (India).

Ephedrine Sulfate Injection USP, 50 mg/mL had annual sales of USD 52 mn in the United States (IQVIA MAT Mar. 2023). The group now has 368 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.

The company's stock was trading 0.55 per cent higher at Rs 518.90 on Wednesday as of 12:13 PM IST.